NEW YORK (GenomeWeb News) – German biotech firm Protagen said today that it has sold its subsidiary Protagen Protein Services to venture capital fund Zukunftsfond Heilbronn.

The sale will provide Protagen with funds to support its diagnostic development efforts, the company said. Financial and other terms of the deal were not disclosed.

Spun out as a 100 percent subsidiary of Protagen in January 2012, Protagen Protein Services offers a variety of protein analysis services aimed at academic labs as well as biopharmaceutical and biosimilars work.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.